Cancer Diagnostics Market analyzes and studies the major market drivers, restraints, and opportunities.
The global cancer diagnostics market is expected to reach $13.1 Billion in 2020 from an estimated $7.1 Billion in 2015, cancer diagnostics market growing at a CAGR of 12.9%.
North America accounted for the largest share of the global cancer diagnostics market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the cancer diagnostics market is expected to experience the highest growth rate in the Asian region, with emphasis on India and China.
These countries are expected to serve as revenue pockets for companies operating in the cancer diagnostics market. Inquire For Complete Report Copy of Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020 at www.reportsnreports.com/contacts/i…aspx?name=402128
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms, garner a greater market share.
According to the CDC, cancer is the second leading cause of mortality, causing ~584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths.
The global Cancer Diagnostics Market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR).
“Cancer Diagnostics Market” spread across 187 pages, profiling 15 companies and supported with 119 tables and 33 figures is now available at www.reportsnreports.com/contacts/d…aspx?name=402128
Some of the major players in the global cancer diagnostics market include Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.), GE Healthcare (U.K.), QIAGEN N.V. (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), and C.R. Bard, Inc. (U.S.).
Key Point from Table of Content
Global Cancer Diagnostics Market, By Technology
Polymerase Chain Reaction (PCR)
in Situ Hybridization (ISH)
Next-Generation Sequencing (NGS)
Magnetic Resonance Imaging (MRI)
Computed Tomography (Ct)
Positron Emission Tomography (PET)
Standalone Positron Emission Tomography
Hybrid Positron Emission Tomography
Global Cancer Diagnostics Market, By Application
Access this Report @ www.reportsnreports.com/purchase.aspx?name=402128